Patient Compliance Difficult in OAB and SUI Markets

Published Online: Tuesday, March 1, 2005

A recent urologist survey found that the average dropout rate for overactive bladder (OAB) medications was estimated at 35% in 2004. "On the positive side, this creates opportunities for new medications to make a mark in the market, either by satisfying unmet therapeutic needs or improving the side-effect and safety profile,"said Linda Liu, a research analyst for Frost & Sullivan, who conducted the survey.

Therefore, improved efficacy, enhanced safety profiles, and lower dosages are likely to play an important role in increasing compliance rates. Improving compliance rates and patient persistency is a challenging task for the OAB and stress urinary incontinence (SUI) markets because the intake of medication is based on the patient's perceived quality of life. Because physicians are the first contact for patients with OAB or SUI, pharmaceutical companies need to use training specialists when introducing drugs with different delivery modes. Direct-to-consumer advertising approaches are also building compliance, as well as educational and awareness campaigns.



Latest Articles
This weekly video program provides our readers with an in-depth review of the latest news, product approvals, FDA rulings and more.
Chronic kidney disease incidence has grown faster than many of its common comorbidities such as diabetes and hypertension, and medications may be an underappreciated driver of this growth.
President Barack Obama’s fiscal year 2017 budget proposal calls for an additional $1.1 billion to combat the nation’s spiraling opioid epidemic.
Baxter International is voluntarily recalling intravenous solution due to leaking containers and the potential for particulate matter.
Latest Issues
$auto_registration$
VSEO N/A